Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of MEDI-546 (anifrolumab) in adults with systemic lupus erythematosus
2012-004619-30Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Primary endpoint: Long-term safety and tolerability of MEDI-546 (anifrolumab). Started Jun 2013; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2012-004619-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004619-30.